Safety, pharmacokinetics and antiviral activity of <scp>ABI‐H2158</scp> , a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study-Reference-Cited by-同舟云学术

Safety, pharmacokinetics and antiviral activity of ABI‐H2158 , a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study

Published:2023-01-12 Issue:3 Volume:30 Page:209-222
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:Journal of Viral Hepatitis

Author:

Agarwal Kosh¹^ORCID,Xu Jia²,Gane Edward J.³^ORCID,Nguyen Tuan T.⁴,Ding Yanhua²,Knox Steven J.⁵,Alves Katia⁵,Evanchik Marc⁵,Zomorodi Katie⁵,Ma Julie⁵,Yan Ran⁵,Huang Qi⁵,Colonno Richard⁵,Stamm Luisa M.⁵,Hassanein Tarek I.⁶,Kim Dong Joon⁷,Lim Young‐Suk⁸^ORCID,Yuen Man‐Fung⁹

Affiliation:

1. Institute of Liver Studies King's College Hospital London UK

2. Phase 1 Clinical Trials Unit The First Hospital of Jilin University Jilin China

3. University of Auckland Auckland New Zealand

4. T Nguyen Research and Education, Inc. San Diego California USA

5. Assembly Biosciences, Inc. South San Francisco California USA

6. Southern California Research Center Coronado California USA

7. Hallym University Chuncheon Sacred Heart Hospital Chuncheon South Korea

8. Asan Medical Centre University of Ulsan College of Medicine Seoul South Korea

9. Department of Medicine University of Hong Kong Hong Kong Hong Kong

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13764

Reference28 articles.

1. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

2. Organization WH.HepatitisB. In:Newsroom WHO ed. Accessed July 8 2022.https://www.who.int/news‐room/fact‐sheets/detail/hepatitis‐b2020

3. Organization WH.Global progress report on HIV viral hepatitis and sexually transmitted infections 2021: accountability for the global health sector strategies 2016–2021: actions for impact.2021.

4. Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

5. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Drug Development in Chronic Hepatitis B Infection: Capsid Assembly Modulators and Nucleic Acid Polymers;Clinics in Liver Disease;2023-11

2. The role of different viral biomarkers on the management of chronic hepatitis B;Clinical and Molecular Hepatology;2023-04-01

3. Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers;Expert Opinion on Drug Discovery;2023-03-21

4. Synthesis and evaluation of N-sulfonylpiperidine-3-carboxamide derivatives as capsid assembly modulators inhibiting HBV in vitro and in HBV-transgenic mice;European Journal of Medicinal Chemistry;2023-03